Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Sirna, Alnylam, Cenix, Bayer, Fisher, Cellomics, CytRx, Nastech, Isis, Lilly, Qiagen, Xantos, Bio-Rad

Sirna, Alnylam, Cenix, Bayer, Fisher, Cellomics, CytRx, Nastech, Isis, Lilly, Qiagen, Xantos, Bio-Rad

Aug 12, 2005
Premium

Sirna Posts Higher Q2 Revenues, Lower Losses

Sirna Therapeutics reported this week a sharp increase in second-quarter revenues, which helped to push down the company's losses.

The company posted revenues of $1.5 million in the quarter, up from $454,000 in the year-ago period, reflecting a surge in fees received from contract manufacturing services.

Sirna's second-quarter net loss arrived at $5.9 million, or $0.14 per share, versus $6.3 million, or $0.18 per share a year earlier.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

New Prototype Test

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

Cell Studies on SARS-CoV-2 Spike Variant, Host Transcriptomes, Glioma-Infiltrating T Cells

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

What's Popular?

In Gene Silencing/Gene Editing

  1. ERS Genomics Licenses CRISPR Patents to Korean Biotech Firm G+FLAS Life Sciences

  2. Cytosine Base Editors Allow Scientists to Study Function of Variants at Scale

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.